Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Dupilumab shows promise in cutting COPD flare-ups and boosting lung function

Dupilumab significantly reduces exacerbations and improves lung function in COPD patients with elevated eosinophil counts, confirming the efficacy of targeting type 2 inflammation.

22 May 2024

Single-cell analysis reveals insights into immune responses during xenotransplantation

Surgical teams at NYU Langone Health performed the world's first genetically modified pig kidney transplants into a human body in September and November 2021, and then transplanted two pig hearts in the summer of 2022.

22 May 2024

Aptamer and Timser partner to deliver world’s first blood test for cervical cancer

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has signed an agreement with Timser Group, a pharmaceutical company focused on women’s health, with a deal value of up to £465,000.

From Aptamer Group 22 May 2024

Tailored antibody-drug conjugate offers hope for aggressive breast cancer

Scientists have used breast cancer cells' weakness against themselves by linking a tumour-selective antibody with a cell-killing drug to destroy hard-to-treat tumors.

21 May 2024

Exercise enhances efficacy of antibody therapy in leukemia patients

Bouts of moderate-to-vigorous intensity exercise could improve the efficacy of antibody therapies used to treat chronic lymphocytic leukemia, new research has shown.

21 May 2024

Dupilumab shows promising results in Phase 3 trial for COPD with type 2 inflammation

Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug -; dupilumab -; that showed rapid and sustained improvements in patients in a pivotal Phase 3 clinical trial, researchers report in the New England Journal of Medicine.

20 May 2024

Enhanced tumor treatment using antibody-loaded extracellular vesicles

Researchers at Karolinska Institutet in Sweden have succeeded in delivering targeted cancer treatment via small membrane bubbles that our cells use to communicate.

20 May 2024

AlphaFold2 can be an effective tool in structure-based drug discovery

One of the most consequential advances in artificial intelligence isn't an eerily conversational chatbot-;it's a new way to unpack the unique 3D structures of proteins.

17 May 2024

Breakthroughs in germline-targeting HIV vaccine design for broad protection

Scientists have made several advances in the design of a class of HIV vaccines that could offer broad protection against the virus, according to four new research papers published this week in Science, Science Translational Medicine, and Science Immunology.

17 May 2024

Study reveals positive impact of repeat COVID-19 vaccinations

Health-care workers received the first doses of the COVID-19 vaccine in December 2020.

17 May 2024

Vaccine candidate spurs elusive type of broadly neutralizing HIV antibodies

An HIV vaccine candidate developed at the Duke Human Vaccine Institute triggered low levels of an elusive type of broadly neutralizing HIV antibodies among a small group of people enrolled in a 2019 clinical trial.

17 May 2024

Novel gene-delivery vehicle shows promise for treating brain disorders

In an important step toward more effective gene therapies for brain diseases, researchers from the Broad Institute of MIT and Harvard have engineered a gene-delivery vehicle that uses a human protein to efficiently cross the blood-brain barrier and deliver a disease-relevant gene to the brain in mice expressing the human protein.

16 May 2024

Research expands understanding of vaccine-induced immune thrombocytopenia and thrombosis

New research led by Flinders University and international experts is expanding understanding of vaccine-induced immune thrombocytopenia and thrombosis (known as VITT).

16 May 2024

Rapid Novor teams up with PMCC to evaluate EasyM™ for multiple myeloma minimal residual disease monitoring

Rapid Novor Inc., a global leader in mass spectrometry (MS)-based antibody protein sequencing, today announced that the first patient has been enrolled in a new clinical study titled 'Clinical evaluation of EasyM™ for disease response analysis in newly diagnosed MM patients (NDMM)'.

From Rapid Novor Inc 16 May 2024

RedShiftBio launches Aurora TX: Revolutionizing RNA and protein analysis with ultra-sensitive microfluidic modulation spectroscopy and thermal ramping capability

RedShiftBio, a leader in innovative biophysical characterization and bioprocess analytical solutions, proudly announces the launch of Aurora TX at The Protein & Antibody Engineering Summit (PEGS), kicking off on May 13, 2024, in Boston, MA. Aurora TX is the company's latest, most advanced instrument featuring ground-breaking MMS technology, and sets a new standard in biomolecular analysis by providing ultra-sensitive, ultra-precise measurements of biomolecule structure and stability, now enhanced with the addition of thermal ramping capability.

From RedShiftBio 16 May 2024

Single measles jab up to 2.6 times more likely to be ineffective in C-section born children

The dynamics of measles immunity at birth and following vaccination.

15 May 2024

Zika virus-specific synthetic molecule can differentiate between prior infections with different flaviviruses

A newly discovered Zika virus-specific synthetic molecule is capable of differentiating Zika-immune patient samples from samples of patients previously infected with the related dengue virus.

14 May 2024

FDA-approved TIVDAK®: Targeting tissue factor in cervical cancer

On April 29th, 2024, the U.S. FDA granted full approval for Seagen Inc.'s TIVDAK® (tisotumab vedotin) targeting tissue factor (TF) for the treatment of patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy. This marks a significant advancement in the therapeutic landscape for cervical cancer, highlighting the potential of antibody-drug conjugates (ADCs) in oncology.

From Sino Biological Inc. 10 May 2024

Breakthrough vaccine strategy guides the immune system to generate HIV neutralizing antibodies

A team led by the Duke Human Vaccine Institute (DHVI) has developed a vaccine approach that works like a GPS, guiding the immune system through the specific steps to make broadly neutralizing antibodies against HIV.

9 May 2024

Longitudinal antibody changes key to identifying peanut allergy resolution in kids

Australian researchers have discovered how changes in antibody levels over time can predict which children are likely to outgrow their peanut allergy.

9 May 2024

Antibody News and Research

Further Reading

Dupilumab shows promise in cutting COPD flare-ups and boosting lung function

Single-cell analysis reveals insights into immune responses during xenotransplantation

Aptamer and Timser partner to deliver world’s first blood test for cervical cancer

Tailored antibody-drug conjugate offers hope for aggressive breast cancer

Exercise enhances efficacy of antibody therapy in leukemia patients

Dupilumab shows promising results in Phase 3 trial for COPD with type 2 inflammation

Enhanced tumor treatment using antibody-loaded extracellular vesicles

AlphaFold2 can be an effective tool in structure-based drug discovery

Breakthroughs in germline-targeting HIV vaccine design for broad protection

Study reveals positive impact of repeat COVID-19 vaccinations

Vaccine candidate spurs elusive type of broadly neutralizing HIV antibodies

Novel gene-delivery vehicle shows promise for treating brain disorders

Research expands understanding of vaccine-induced immune thrombocytopenia and thrombosis

Rapid Novor teams up with PMCC to evaluate EasyM™ for multiple myeloma minimal residual disease monitoring

RedShiftBio launches Aurora TX: Revolutionizing RNA and protein analysis with ultra-sensitive microfluidic modulation spectroscopy and thermal ramping capability

Single measles jab up to 2.6 times more likely to be ineffective in C-section born children

Zika virus-specific synthetic molecule can differentiate between prior infections with different flaviviruses

FDA-approved TIVDAK®: Targeting tissue factor in cervical cancer

Breakthrough vaccine strategy guides the immune system to generate HIV neutralizing antibodies

Longitudinal antibody changes key to identifying peanut allergy resolution in kids

Immunology eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News